The Indian Council of Medical Research (ICMR), the apex body for the formulation, coordination and promotion of biomedical research, is in talks with Indian drug major Sun Pharma to create a structure to fund Clinical research in the country.
An ICMR-Sun Pharma joint working group met recently to discuss ways to improve heathcare innovations in the country by conducting disease burden studies and clinical trials in well-characterised sites, which have a high burden of specific diseases as well as healthcare facilities and experts who could diagnose, treat and monitor patients over time.
The group is considering a hub-and-spoke model of clinical trial and research sites as well as specialised laboratories, said a senior official of Sun Pharma. Infectious diseases like dengue and TB are high on the group’s priority list.
The working group is also considering to set up a central unit linked to ICMR to manage the “well-characterised sites, distributed across the country based on the burden of the disease being studied, he said.
The project may require Rs 6 crore-Rs 40 crore in funding. The joint working group is also expected to put together a policy paper by the time it meets again in March 2017 and will seek inputs on it from academicians and the industry, the official said.